Protein Design Labs (PDLI): Stock strong Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Protein Design Labs (PDLI): Stock strong

PDLI 2.470

0.0%

Jan 18 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	12/17/2007 10:30:30 AM
	of 407

PDL Biopharma sells oncology drug rights for $200 mln Dec 17 (Reuters) - PDL BioPharma Inc (PDLI.O: Quote, Profile, Research) said it will sell the rights to its oncologic product, IV Busulfex, to Japanese drug company, Otsuka Pharmaceutical Co. Ltd, for $200 million in cash. The deal, which includes trademarks, patents, intellectual property and related assets, follows PDL's decision in October this year to pursue sale of its main assets. (Reporting by Niveditha Ravi in Bangalore, Editing by Dinesh Nair)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next